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ABSTRACT 
Han, Xu. M.S., Purdue University, December 2014. Design and Synthesis of Small-
Molecule Protein-Protein Interaction Antagonists. Major Professor: Samy Meroueh. 
Protein-protein interactions play a crucial role in a wide range of biological processes. 
Research on the design and synthesis of small molecules to modulate these protein-
protein interactions can lead to new targets and drugs to modulate their function. In 
Chapter one, we discuss the design and synthesis of small molecules to probe a protein-
protein interaction in a voltage-gated Ca
2+
 channel. Virtual screening identified a 
compound (BTT-3) that contained a 3,4-dihydro-3,4’-pyrazole core. This compound had 
modest biological activity when tested in a fluorescence polarization (FP) assay. The 
synthetic route to BTT-3 consisted of six steps. In addition, analogs of BTT-3 were made 
for a structure-activity study to establish the importance of a carboxylate moiety. We also 
synthesized a biotinylated benzophenone photo-affinity probe and linked it to BTT-3 to 
identify additional protein targets of the compound. In Chapter two, small-molecule 
antagonists targeting uPA-uPAR protein-protein interaction are presented. A total of 500 
commercially-available compounds were previously identified by virtual screening and 
tested by a FP assay. Three classes of compounds were found with biological activity. 
The first class of compounds contains pyrrolidone core structures represented by IPR-
1110, the second class has a novel pyrrolo[3,4-c]pyrazole ring system, represented by
xv 
 
IPR-1283 and the last series had compounds with a 1,2-disubstituted 1,2-
dihydropyrrolo[3,4-b]indol-3(4H)-one core structure, represented by IPR-540. Each of 
these three compounds were synthesized and assessed by FP and ELISA assays.  A 
binding mode of IPR-1110 with uPA was subsequently proposed. Based on this binding 
mode, another 61 IPR-1110 derivatives were synthesized by us to illustrate the SAR 
activity. Analogs of the other two series were also synthesized. 
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CHAPTER 1. STRUCTURE-BASED DRUG DESIGN AND SYNTHESIS 
TARGETING Ca
2+ 
CHANNEL PROTEIN-PROTEIN INTERACTIONS 
1.1  Introduction 
1.1.1 Antagonists Targeting Ca
2+
 Channel Protein-Protein Interactions 
        Protein-protein interactions play an essential role in a number of biological 
processes, such as the formation of protease-inhibitor, antigen-antibody and hormone-
receptor complexes.
1
 Protein-protein interactions are intrinsically important to study the 
role of allostery. In addition, protein-protein interactions provide an avenue to understand 
protein folding. It is known that there are three major forces that drive protein-protein 
interactions; they include hydrophobicity, hydrogen bonding, and van der Waals 
interactions. In addition, protein-protein interactions are also an important source of new 
drug targets.
2-5
  
  Ca
2+
 plays a crucial role in biological processes and it is the second messenger of 
electrical signaling. Ca
2+
 can initiate intracellular events including secretion, synaptic 
transmission and gene expression. In addition, the influx of Ca
2+ 
through voltage-gated 
Ca
2+
 channels (VGCCs) regulates various cellular processes, including tumorigenesis, 
cell migration and cell death. These VGCCs are the main Ca
2+
 entryways to nerve and 
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muscle cells.
6,7
 These high-voltage Ca
2+ 
channels are plasma membrane proteins that 
consist of four subunits, including α1, α2δ, β and γ (Fig. 1.1).
6
 Cavα1 is the pivotal subunit 
of voltage-gated Ca
2+
 channels and this subunit contains most drug binding sites and 
channel pore. The β subunit (Cavβ) is essential in regulation of Ca
2+
 channels by G 
proteins and protein kinases.
8-11
 In addition, this subunit also plays a crucial role in 
regulating the surface expression of high-voltage activated Ca
2+ 
channels and directly 
modulates gene transcription. 
 
Figure 1.1. Organization of voltage-gated Ca
2+
 channels 
The molecular structure of Cavβ was reported in 1998,
12-14
 and the crystal 
structure of Cavβ was also reported in 2004 (Fig. 1.2). The structure showed three main 
3 
 
 regions at the N-terminus, including an SH3 domain (residues 60-120 and 170-175, 
gold), a HOOK region (residues 121-169, purple) and a GK domain (residues 176-360, 
green).
6,15-17
  
 
Figure 1.2.  Crystal structure of Cavβ core 
   In the cytoplasmic loop of Cavα1, there is a high-affinity site where Cavβ binds. 
This site is known as the α-interaction domain (AID) and the conformation of AID is an 
α-helix that binds to a hydrophobic pocket in the GK domain. In addition, there is a β-
interaction domain (BID) that directly binds to AID. The BID domain is the primary area 
that the β-subunit uses to associate with α1. The significance of this interaction was 
reported and suggests that interactions between Cavβ and Cavα1 can have an effect of 
normal physiological function and pathophysiological processes.
18-22
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 Research in our group mainly focuses on discovering and developing a small 
molecule to inhibit the interaction of Cavα1 and Cavβ. Screening libraries of 500,000 
compounds from ChemDiv were docked to Cavβ protein and ranked according to 
GlideScore. The top 88 compounds were purchased and assessed by FP (fluorescence 
polarization) assay at 50 µM. The results yielded one compound (BTT-3) that showed 
concentration-dependent inhibition of AID binding to Cavβ. A binding mode of BTT-3 
was proposed (Fig. 1.3). These studies were carried out by members of the Meroueh 
laboratory. 
 
Figure 1.3. (a) Binding mode of BTT-3. (b) Chemical structure of BTT-3 
Met29 
Arg141 
Ser140 
Leu137 
Arg136 
Val133 
Asn174 
Gln175 
Leu176 
Met30 
Val126 
Val128 
Ser130 
Asp177 
BTT-3 
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     A synthetic route to BTT-3 and its derivatives was proposed and implemented. To 
identify additional targets of BTT-3, we developed a biotinylated benzophenone photo-
affinity probe that was linked to BTT-3.  
1.1.2 Photo-affinity Probe 
Photo-affinity labeling was first discovered and reported by F.H.Westheimer in 
1962.
23
 It has become a highly efficient tool in identification of target proteins of 
biological molecules,
24,25
 and protein-protein complexes.
26-29
 A photo-affinity probe is 
composed by three major parts: a photoreactive functional group, such as diazirines or 
benzophenones,
30-32
 a biological scaffold, and an indicator unit.
33
 Generally, a biotin tag 
is the indicator group in photo-affinity probes because of its specificity and sensitivity to 
immunological methods.   
Although a number of photo-affinity groups have been developed, benzophenones 
have several advantages. First, benzophenones are chemically stable, even more stable 
than diazirines.
32
 Second, benzophenones can be activated at 350-360 nm, which is a 
wavelength that is beyond the range of protein-damaging wavelength. The activation of 
the inert benzophenone group can be triggered by UV light and then highly reactive 
electrophilic radicals will be created to form a covalent bond with the protein.
34
 The 
mechanism of this activation was reported by Gyorgy Dormtin in 1994.
32
   
We have strong interest in identifying additional target protein(s) of BTT-3 in order 
to gain more knowledge of the biological activity of this compound and to help us design  
6 
 
and explore new derivatives in the future. Thus a biotinylated benzophenone photo-
affinity probe was synthesized through a six-step synthesis and its chemical structure is 
shown in Fig. 1.4. 
 
Figure 1.4. Chemical structure of photo-affinity probe 
 The biotinylated benzophenone photo-affinity probe was linked to the synthesized 
BTT-3 via a simple coupling reaction and the chemical structure of the BTT-3 photo-
affinity reagent is shown in Fig. 1.5.  
 
Figure 1.5. Chemical structure of BTT-3 photo-affinity reagent 
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1.2  Results and Discussion 
1.2.1 Chemical Synthesis of BTT-3 
BTT-3 is a compound that has biological activity targeting Ca
2+
 channel protein-
protein interactions in neuropathic pain. Retrosynthetically, BTT-3 can be synthesized via 
hydrolysis of its precursor,
35
 the methyl ester derivative 5, which can be achieved via a 
coupling reaction of commercially available methyl-4-chloro-4-oxobutyrate and a 
secondary free amine in 4.
36,37
 The secondary amine in 4,5-dihydro-1H-pyrazole could in 
turn be generated via Michael addition by excessive hydrazine hydride, simplifying the 
structure to 3.
38
 The latter can be prepared from 2 through an Aldol condensation.
39,40
 The 
pyrazole core structure along with free aldehyde group in 3 was accessible from 
phenylhydrazine and 4’-methylacetophenone41 involving a condensation/Vilsmeier-
Haack reaction sequence (Scheme 1.1).
42,43
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Scheme 1.1. Synthetic scheme of BTT-3 
With commercially available phenylhydrazine and 4’-methylacetophenone, the 
synthesis of 1 was achieved by simple condensation in good yield. But the desired 
product was very sensitive to visible light. It decomposed when exposed to light and was 
easily oxidized when exposed to air. Thus, this compound was handled with special care 
by storing in darkness, under argon gas and at 4 °C. 
9 
 
The second step in Scheme 1.1 is key to generate the pyrazole ring core of BTT-3. 
This was achieved by adding excess Vilsmeier reagent (DMF+POCl3) to 1. The reaction 
occurs through a Vilsmeier-Haack reaction resulting in pyrazole structure 2 that contains 
a free aldehyde group. Condensation with substituted acetophenones yielded the enone 3, 
which was subsequently coupled with excess hydrazine hydride to yield the second 3,4-
dihydropyrazole ring 4.  
When exploring the reaction conditions for the acetylation of 4 and commercially-
available methyl-4-chloro-4-oxobutyrate, the two common methods employed consisted 
of using DCM as the solvent followed by addition of 3 equivalents of TEA. Alternatively, 
the reaction was carried out using anhydrous pyridine as solvent. Pyridine was a good 
solvent as evidenced by the purity of the desired product 5. 
Finally, the hydrolysis of 5 was achieved by using 2 M KOH aqueous solution in 
methanol refluxed for 16 h to afford 6 in good yield. It is of interest to note that using 2 
M NaOH aqueous solution results in lower yields. Also the procedure was faster when 
compared to using 2 M LiOH, which required 3 days to go to completion. The 
disadvantage in using 2 M KOH solution was that the base was strong enough to break 
down the amide bond formed via acetylation of methyl-4-chloro-4-oxobutyrate and 4. 
But this could be avoided by limiting reaction time to less than 16 h.  
1.2.2 Structure Based Modification of BTT-3 
Based on the binding mode of 6 shown in Fig. 1.3, the terminal carboxylic acid group 
in P1 interacts with an Arg141 residue on the protein side chain through a salt bridge 
interaction. To probe this predicted binding mode, four additional BTT-3 derivatives 
10 
 
were prepared, namely 6a to 6d. In these derivatives, the carboxylic acid group was 
replaced with a neutral moiety. The synthetic scheme for preparation of 6b to 6d is 
shown in Scheme 1.2. The efficiency of 6a to 6d along with 5 has been assessed in 
biochemical assays by my colleagues in the Meroueh laboratory. A fluorescence 
polarization assay was used for this purpose. The assay consisted of a fluorescently-
labeled AID peptide (AID-FAM). Active compounds are expected to displace AID-FAM 
and significantly increase polarization. Testing of the derivatives showed no effect on 
AID-FAM binding suggesting that the carboxylic acid on BTT-3 is essential for binding 
to the protein. 
 
Scheme 1.2. Synthetic scheme of 6b to 6d 
11 
 
1.2.3 Synthesis of BTT-3 Photo-affinity Reagent 
Photo-affinity probe 12 can be achieved through a six-step synthesis (Scheme 1.3). 
Compound 7 was prepared with 4,4’-dihydroxybenzophenone and propargyl bromide 
through a simple SN2 reaction.
44
 Mitsunobu coupling was used staring with DIAD in 
toluene (40% w/v) added to the mixture of triphenylphosphine, 7 and 8 in anhydrous 
THF to afford 9.
45,46
 Biotin is coupled with the azide linker using EDCI and HOBt to 
yield 10,
47
 which in turn reacted with compound 9 through a Huisgen cycloaddition to 
yield 11.
48
 The protecting group in 11 was removed to afford the final biotinylated 
benzophenone photo-affinity probe, namely compound 12.
49
   
 
Scheme 1.3. Synthetic scheme of photo-affinity probe 
12 
 
The final BTT-3 photo-affinity reagent 13 can be prepared through a simple coupling 
reaction between 6 and the photo-affinity probe 12 (Scheme 1.4).
50 
The reagent 13 was 
characterized by LC/MS. 
 
Scheme 1.4. Synthetic scheme of BTT-3 photo-affinity probe 
It should be noted that in the first step, it is unavoidable to get both the desired 
product 7 and the di-alkyne substituted side product. However, the pure product 7 can be 
achieved by flash chromatography. In addition, the Mitsunobu coupling reaction always 
takes a long time and it has to be performed in darkness since the coupling reagent DIAD 
is very sensitive to visible light and easily decomposes. In the coupling reaction of biotin 
and the azide linker, because there are no UV-Visible absorption groups in both of the 
reactants and final product, it is difficult to monitor the reaction progress by either TLC 
or LC/MS. The final product was visualized by a phosphomolybdate stain. 11 is then 
achieved through Huisgen cycloaddition of 9 and 10 and was characterized by HRMS, 
1
H 
NMR and 
13
C NMR. Then the protection group in 11 was removed to afford the final 
photo-affinity probe 12, which was used in next reaction without further purification to 
13 
 
afford the final BTT-3 photo-affinity reagent. This reagent was only identified by LC/MS 
and it will be further identified by 
1
H NMR and 
13
C NMR in the future. 
1.3 Experimental 
General Methods:  All chemicals were purchased from either Sigma-Aldrich or Acros 
and used as received. Column chromatography was carried out with silica gel GF254 (25-
63μm). Mass Spectra were measured on an Agilent 6520 Mass Q-TOF instrument. 1H 
NMR and 
13
C NMR spectra were recorded on a BRUKER 500 MHz spectrometer, using 
TMS as an internal standard and CDCl3 or DMSO-d6 as solvents. Chemical shifts (δ 
values) and coupling constants (J values) are reported in ppm and hertz, respectively. 
Anhydrous solvent and reagents were all analytically pure and dried through routine 
protocols. All compounds that were evaluated in biological essays had > 95% purity 
using HPLC. 
1.3.1 Chemical Synthesis of BTT-3 
 
4-Methylacetophenone phenylhydrazone (1). 4’-Methylacetophenone (0.95 g, 7.1 mmol) 
was dissolved in 95% ethyl alcohol (7 mL) followed by phenylhydrazine (0.68 mL, 6.9 
mmol) and 3-5 drops of HOAc. The mixture was stirred under ambient temperature for 
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30 min, and then was heated to reflux for an additional 15 h. The resulting brown-yellow 
solution was cooled to room temperature and then ice-H2O (20 mL) was added. Grey 
solid was filtered off, washed with ice-H2O and hexane, respectively. The solid was then 
dried under high vacuum (1.31 g, 85%): 
1
H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.0 
Hz, 2H), 7.28 (t, J = 8.0 Hz, 2H), 7.17-7.19 (m, 4H), 6.87 (t, J = 7.5 Hz, 1H), 2.37 (s, 3H), 
2.23 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 145.45, 141.97, 138.05, 136.38, 129.34, 
129.15, 125.62, 120.19, 113.34, 21.30, 12.03; HRMS (ESI) m/z for C15H16N2 [M + H]
+
 
calcd 225.1386, found 225.1381. 
 
3-(4-Methylphenyl)-1-phenyl-4-pyrazolecarboxaldehyde (2). To an oven-dried 50 mL 
round bottom flask was added anhydrous DMF (10 mL) which was cooled to 0 °C in an 
ice bath before adding POCl3 (2.0 mL, 21.44 mmol) dropwise. Compound 1 (1.20 g, 5.36 
mmol) was poured into the solution and the resulting mixture was warmed to room 
temperature then was heated to 50-60 °C. The reaction was stopped after 20 h and the 
resulting dark-red solution was quenched by pouring into stirred slurry of ice. Saturated 
NaHCO3 solution was added dropwise to adjust to afford pH 7. Yellow precipitate was 
filtered and washed with ice-H2O to give the desired product and the solid was dried 
under high vacuum (1.32 g, 94%): 
1
H NMR (500 MHz, CDCl3) δ 10.05 (s, 1H), 8.53 (s, 
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1H), 7.79 (d, J = 8.5 Hz, 2H), 7.71(d, J = 8.5 Hz, 2H), 7.51(t, J = 8.5 Hz, 2H), 7.40(t, J = 
7.5 Hz, 1H), 7.31(d, J = 8 Hz, 2H), 2.43(s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 185.37, 
154.95, 139.41, 139.14, 130.93, 129.73, 129.54, 128.92, 128.55, 127.96, 122.55, 119.81, 
21.44; HRMS (ESI) m/z for C17H14N2O [M + H]
+
 calcd 263.1179, found 263.1172. 
 
1-(4-Methoxyphenyl)-3-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-2-propen-1-one 
(3). Acetanisole (1.05 g, 4 mmol), aldehyde 2 (600.7 mg, 4 mmol) and KOH pellets (600 
mg, 10.7 mmol) were mixed in a 50 mL round bottom flask containing 95% alcohol (20 
mL). The mixture was stirred at ambient temperature for 20 h. Yellow solid was filtered 
off and washed with cold alcohol (3 x 20 mL). The solid was dried under high vacuum to 
afford the desired product 3 (1.28 g, 81%): 
1
H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H), 
7.97 (d, J = 8.5 Hz, 2H), 7.87 (d, J = 15.5 Hz, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 
8 Hz, 2H), 7.50 (t, J = 8 Hz, 2H), 7.37 (d, J = 15.5 Hz, 1H), 7.35 (t, J = 7.5 Hz, 1H), 7.30 
(d, J = 8 Hz, 2H), 6.97 (dd, J = 7, 2 Hz, 2H), 3.88 (s, 3H), 2.42 (s, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 188.48, 163.41, 153.93, 139.63, 138.66, 134.77, 131.28, 130.77, 129.64, 
129.56, 128.78, 127.20, 126.73, 121.40, 119.43, 118.51, 113.90, 55.58, 21.46; HRMS 
(ESI) m/z for C26H22N2O2 [M + H]
+
 calcd 395.1754, found 395.1745. 
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5-(4-Methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-3,4'-bipyrazole (4). To a 
solution of propen-1-one 3 (1.20 g, 3.04 mmol) in 95% ethanol (40 mL) was added 50-60% 
hydrazine hydrate (0.6 mL, 12.2 mmol) dropwise at room temperature then the resulting 
mixture was refluxed for 24 h to yield white precipitate. The reaction was then cooled to 
0 °C in an ice bath. The resulting precipitate was filtered, washed with ice-water (5 x 20 
mL) and dried under high vacuum to give product 4 as a white solid (894 mg, 72%): 
1
H 
NMR (500 MHz, CDCl3) δ 8.05 (s, 1H), 7.72 (d, J = 7.5 Hz, 2H), 7.60-7.63 (m, 4H), 7.42 
(t, J = 8 Hz, 2H), 7.27-7.28 (m, 3H), 6.91 (d, J = 9 Hz, 2H), 5.14 (t, J = 9 Hz, 1H), 3.83 (s, 
3H), 3.44-3.49 (dd, J = 16, 10 Hz, 1H), 3.03-3.09 (dd, J = 16, 8.5 Hz, 1H), 2.41 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 160.48, 152.39, 151.18, 140.06, 138.13, 130.33, 129.49, 
128.09, 127.69, 126.49, 125.85, 125.63, 123.22, 119.04, 114.12, 55.81, 55.45, 41.18, 
21.41; HRMS (ESI) m/z for C26H24N4O [M + H]
+
 calcd 409.2023, found 409.2014. 
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Methyl-4-(5-(4-methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-
bipyrazol]-2-yl)-4-oxobutanoate (5). Compound 4 (817 mg, 2.0 mmol) was dissolved in 
anhydrous pyridine (10 mL). The resulting mixture was cooled to 0 °C and methyl-4-
chloro-4-oxobutyrate (0.25 mL, 4.0 mmol) was added dropwise. The reaction was heated 
to reflux for 4 h and then was quenched by pouring the solution into ice-H2O (20 mL). 
The resulting precipitate was filtered off and washed with water. The crude solid was 
purified by flash chromatography eluting with 30% ethyl acetate/hexanes to give a white 
solid (0.87 g, 83%): Rf = 0.15 (30% ethyl acetate/hexanes): 
1
H NMR (500 MHz, CDCl3) δ 
7.92 (s, 1H), 7.77 (d, J = 7.5Hz, 2H), 7.65 (d, J = 8 Hz, 2H), 7.61 (2H, J = 9 Hz, 2H), 
7.39 (t, J = 8.5 Hz, 2H), 7.21-7.26 (m, 4H), 6.89 (d, J = 8.5 Hz, 2H), 5.90-5.93 (dd, J = 
11.5, 4 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 3H), 3.56-3.62 (dd, J = 17, 11.5 Hz, 1H), 3.56-3.42 
(m, 1H), 3.03-3.07 (dd, J = 17, 4 Hz, 1H), 2.85-2.97 (m, 2H), 2.68-2.73 (m, 1H), 2.39 (s, 
3H); 
13
C NMR (125 MHz, CDCl3) δ 173.94, 169.61, 161.52, 154.42, 150.00, 140.10, 
137.94, 130.51, 129.47, 129.30, 128.41, 128.16, 126.24, 124.10, 122.25, 119.01, 114.19, 
100.13, 55.52, 52.81, 51.86, 42.11, 29.14, 28.84, 21.43; HRMS (ESI) m/z for C31H30N4O4 
[M + H]
+
 calcd 523.2340, found 523.2339. 
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4-(5-(4-Methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-yl)-
4-oxobutanoic acid (6). A solution of compound 5 (522.6 mg, 1 mmol) and 2 M KOH 
aqueous solution (2.4 mL) in methanol (12 mL) was heated to reflux for 16 h. The 
reaction was cooled to room temperature. Solvent was removed in vacuo and the crude 
residue was acidified with 1 M HCl solution to yield white precipitate. The resulting solid 
was filtered off, washed with ice-H2O and dried under high vacuum to afford white solid 
(442.5 mg, 87%): 
1
H NMR (500 MHz, DMSO-d6) δ 8.23 (s, 1H), 7.85 (d, J = 8 Hz, 2H), 
7.67-7.71 (m, 4H), 7.47 (t, J = 8 Hz, 2H), 7.29 (m, 3H), 6.99 (d, J = 8.5 Hz, 2H), 5.67-
5.70 (dd, J = 11.5, 5 Hz, 1H), 3.85-3.88 (m, 1H), 3.82 (s, 3H), 3.11-3.17 (m, 1H), 3.06-
3.10 (m, 1H), 2.82-2.88 (m, 1H), 2.53-2.55 (m, 2H), 2.36 (s, 3H); 
13
C NMR (125 MHz, 
DMSO-d6) δ 173.99, 168.75, 160.85, 153.82, 149.15, 139.34, 137.30, 129.99, 129.43, 
129.17, 128.29, 127.74, 126.24, 126.09, 123.73, 123.14, 118.09, 114.12, 99.50, 55.31, 
51.99, 42.01, 28.73, 28.49, 20.83; HRMS (ESI) m/z for C30H28N4O4 [M + H]
+
 calcd 
509.2183, found 509.2185. 
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1.3.2 Chemical Synthesis of BTT-3 Derivatives 
General procedures for synthesis of 6c to 6d: HATU (114 mg, 0.3 mmol), carboxylic acid 
(0.3 mmol) and TEA (0.08 mL, 0.6 mmol) were dissolved in anhydrous DMF solution (2 
mL) and the resulting mixture was stirred for 30 min at room temperature. Compound 4 
(82 mg, 0.2 mmol) was then slowly added and the mixture was stirred for 20 h at ambient 
temperature. Ethyl acetate (5 mL) was added. The mixture was washed with saturated 
NaHCO3 solution, H2O and brine, respectively. The collected organic layer was dried 
over anhydrous MgSO4 and concentrated in vacuo. The crude residue was purified by 
flash column chromatography (3:1 hexane/ethyl acetate) to afford the desired 
compound.
50
 
 
Isopropyl-4-(5-(4-methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-
bipyrazol]-2-yl)-4-oxobutanoate (6a). Compound 6 (50 mg, 0.1 mmol) was dissolved in 
isopropyl alcohol (2 mL) and the mixture was stirred at 0 °C. Thionyl chloride (0.02 mL, 
0.3 mmol) was added dropwise. The reaction was warmed to ambient temperature and 
stirred for 5 h. Solvent was removed in vacuo and DCM (2 mL) was then added. The 
crude residue was basified by saturated NaHCO3 solution and extracted by DCM (2 x 10 
mL). The organic extracts were dried over anhydrous MgSO4, and solvent was removed 
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in vacuo to afford the resulting compound as a white solid (46 mg, 85%): 
1
H NMR (500 
MHz, CDCl3) δ 7.96 (s, 1H), 7.77 (d, J = 8 Hz, 2H), 7.65 (d, J = 8 Hz, 2H), 7.60 (d, J = 9 
Hz, 2H), 7.38 (t, J = 8.5 Hz, 2H), 7.24 (d, J = 8 Hz, 2H), 7.20 (d, J = 7.5 Hz, 1H), 6.88 (d, 
J = 8.5 Hz, 2H), 5.91-5.94 (dd, J = 11, 4 Hz, 1H), 4.98-5.07 (m, 1H), 3.83 (s, 3H), 3.56-
3.61 (m, 1H), 3.35-3.42 (m, 1H), 3.02-3.06 (dd, J = 13, 4 Hz, 1H), 2.82-2.93 (m, 2H), 
2.63-2.69 (m, 1H), 2.39 (s, 3H), 1.5-1.6 (brs, 1H), 1.25 (d, J = 6.5 Hz, 3H), 1.19 (d, J = 6 
Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 173.05, 169.77, 161.51, 154.30, 149.98, 140.16, 
137.91, 130.60, 129.48, 129.27, 128.41, 128.15, 126.36, 126.19, 124.19, 122.27, 119.00, 
114.19, 100.15, 68.13, 55.53, 52.84, 42.08, 29.42, 29.14, 21.98, 21.44; HRMS (ESI) m/z 
for C33H34N4O4 [M + H]
+
 calcd 551.2653, found 551.2662. 
 
(3-Methoxyphenyl)(5-(4-methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-
bipyrazol]-2-yl)methanone (6b). Compound 4 (816 mg, 2 mmol) was dissolved in dry 
DCM (10 mL) and the mixture was cooled to 0 °C. 3-Methoxybenzoyl chloride (0.56 mL, 
4 mmol) was added dropwise and followed by TEA (0.84 mL, 6 mmol). The mixture was 
warmed to ambient temperature and stirred for 12 h. H2O (5 mL) was added and the 
mixture was extracted with DCM (2 x 10 mL). The combined organic layer was then 
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washed with brine and dried over anhydrous MgSO4. Solvent was removed in vacuo and 
the crude residue was purified by flash chromatography eluting with 30% ethyl 
acetate/hexanes to give a white solid (0.9 g, 82%): Rf = 0.2 (30% ethyl acetate/hexanes): 
1
H NMR (500 MHz, DMSO-d6) δ 8.50 (s, 1H), 7.89 (d, J = 8 Hz, 2H), 7.71 (d, J = 8 Hz, 
2H), 7.64 (d, J = 8.5 Hz, 2H), 7.46 (t, J = 7.5 Hz, 3H), 7.41-7.43 (m, 1H), 7.37-7.40 (m, 
1H), 7.28-7.31 (m, 3H), 7.08-7.10 (dd, J = 8, 2 Hz, 1H), 7.01 (d, J = 9 Hz, 2H), 5.84-5.88 
(dd, J = 12, 5.5 Hz, 1H), 3.89-3.95 (m, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.22-3.27 (m, 1H), 
2.38 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 167.10, 164.97, 160.93, 158.46, 154.78, 
149.73, 139.36, 136.08, 130.11, 129.40, 129.13, 128.66, 128.35, 128.01, 126.36, 126.13, 
123.73, 123.38, 121.89, 121.52, 118.16, 116.37, 114.93, 114.19, 113.89, 55.33, 55.23, 
52.97, 41.67, 20.85; HRMS (ESI) m/z for C34H30N4O3 [M + H]
+
 calcd 543.2391, found 
543.2396. 
 
1-(5-(4-Methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-
yl)pentane-1,4-dione (6c). Compound 6c was prepared through a coupling reaction of 4 
and levulinic acid in a manner similar to that described in general procedures for 
synthesis of 6c to 6d. Yield 46%, white solid: 
1
H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 
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7.77 (d, J = 7.5 Hz, 2H), 7.65 (d, J = 8 Hz, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.40 (t, J = 7.5 
Hz, 2H), 7.21-7.25 (m, 3H), 6.88 (d, J = 8.5 Hz, 2H), 5.88-5.91 (dd, J = 11, 4 Hz, 1H), 
3.83 (s, 3H), 3.56-3.61 (m, 1H), 3.30-3.35 (m, 1H), 3.02-3.06 (m, 1H), 2.95-3.00 (m, 1H),  
2.87-2.93 (m, 1H), 2.78-2.84 (m, 1H), 2.39 (s, 3H), 2.23 (m, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 207.91, 169.98, 161.50, 154.29, 149.97, 140.10, 137.91, 130.51, 129.45, 129.32, 
128.38, 128.15, 126.23, 126.12, 124.15, 122.32, 119.03, 114.18, 100.12, 55.50, 52.77, 
42.13, 38.03, 30.16, 28.21, 21.40; HRMS (ESI) m/z for C31H30N4O3 [M + H]
+
 calcd 
507.2391, found 507.2384. 
 
(5-(4-Methoxyphenyl)-1'-phenyl-3'-(p-tolyl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-2-
yl)(thiophen-2-yl)methanone (6d). Compound 6d was prepared through a coupling 
reaction of 4 and 2-thiophenecarboxylic acid in a manner similar to that described in 
general procedures for synthesis of 6c to 6d. Yield 62%, brown red solid: 
1
H NMR (500 
MHz, DMSO-d6) δ 8.41 (s, 1H), 8.01-8.02 (dd, J = 4, 1.5 Hz, 1H), 7.91-7.92 (dd, J = 5, 1 
Hz, 1H), 7.86 (d, J = 8 Hz, 2H), 7.82 (d, J = 9 Hz, 2H), 7.71 (d, J = 8 Hz, 2H), 7.44 (t, J 
= 7.5 Hz, 2H), 7.29 (d, J = 8 Hz, 2H), 7.26 (d, J = 7.5 Hz, 1H), 7.19-7.21 (dd, J = 5, 3.5 
Hz, 1H), 7.08 (d, J = 9 Hz, 2H), 5.82-5.85 (dd, J = 11.5, 5.5 Hz, 1H), 3.92-3.97 (m, 1H), 
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3.83 (s, 3H), 3.25-3.29 (m, 1H), 2.36 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 161.11, 
157.77, 155.16, 149.78, 139.32, 137.34, 135.17, 133.96, 133.88, 130.03, 129.38, 129.12, 
128.69, 128.08, 126.85, 126.43, 126.13, 123.63, 123.20, 118.14, 114.28, 55.39, 52.99, 
41.76, 20.85; HRMS (ESI) m/z for C31H26N4O2S [M + H]
+
 calcd 519.1849, found 
519.1849. 
1.3.3 Synthesis of BTT-3 Photo-affinity Reagent 
 
(4-Hydroxyphenyl)[4-(2-propyn-1-yloxy)phenyl]-methanone (7). To a solution of 4,4ʼ-
dihydroxybenzophenone (1.7 g, 8 mmol) and K2CO3 (552 mg, 4.0 mmol) in dry DMF (20 
mL) was added propargyl bromide (80 wt % in toluene, 0.52 mL, 4.0 mmol) at room 
temperature over 15 minutes. The resulting mixture was stirred at 80-85 °C for 17 h. The 
reaction was cooled to room temperature and quenched with H2O (20 mL). The solution 
was extracted with ethyl acetate (3 x 20 mL) and the combined organic extracts were 
washed with saturated NaHCO3 solution (2 x 30 mL) and brine (2 x 30 mL), respectively. 
The organic layer was dried over anhydrous MgSO4 and concentrated in vacuo. Flash 
column chromatography (3:1, hexane/ethyl acetate) afforded compound 7 as a white 
powder (686 mg, 68%): Rf = 0.2 (30% ethyl acetate/hexanes); 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.70 (d, J = 9 Hz, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 2H), 
6.89 (d, J = 8.5 Hz, 2H), 4.92 (s, 2H), 3.64 (s, 1H); 
13
C NMR (125 MHz, DMSO-d6) δ 
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193.16, 161.65, 160.26, 132.29, 131.61, 131.10, 128.47, 115.22, 114.58, 78.88, 78.75, 
66.76; HRMS (ESI) m/z for C16H12O3 [M + H]
+
 calcd 253.0859, found 253.0853. 
 
Tert-butyl-(2-(2-hydroxyethoxy)ethyl)carbamate (8). 2-(2-Aminoethoxy)-ethanol (1.00 
mL, 10 mmol) was dissolved in THF (20 mL) at 0 °C and 1 M NaOH aqueous solution 
(5.0 mL) was added and followed by di-tert-butyl dicarbonate (2.46 g, 11.3 mmol). Ice 
bath was removed and the resulting mixture was stirred at ambient temperature for 20 h. 
After removal of the solvent, the resulting mixture was extracted with ethyl acetate (3 x 
20 mL). The combined organic extracts were washed with brine, dried over anhydrous 
MgSO4 and concentrated in vacuo. The crude residue was purified by flash 
chromatography (100% ethyl acetate) to give the desired product 8 (1.97 g, 96%) as a 
colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 3.73 (t, J = 4 Hz, 2H), 3.57 (t, J = 4.5 Hz, 
2H), 3.54 (t, J = 5 Hz, 2H), 3.32 (t, J = 5 Hz, 2H), 1.44 (s, 9H); 
13
C NMR (125 MHz, 
DMSO-d6) δ 156.12, 72.21, 70.30, 61.70, 40.37, 28.39, 27.40; HRMS (ESI) m/z for 
C9H19NO4 [M + Na]
+
 calcd 228.1206, found 228.1206. 
 
Tert-butyl(2-(2-(4-(4-(prop-2-yn-1-yloxy)benzoyl)phenoxy)ethoxy)ethyl)carbamate (9). 
To a mixture of compound 7 (1.39 g, 5.5 mmol), 8 (1.13 g, 5.5 mmol) and Ph3P (1.73 g, 
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6.6 mmol) in anhydrous THF (20 mL) was added diisopropyl azodicarboxylate (DIAD) 
in anhydrous toluene solution (1.4 mL, 7.2 mmol, 40% w/v) dropwise under 0 °C. The 
ice bath was removed and the reaction was kept in darkness and stirred at ambient 
temperature for 48 h. The reaction was diluted with ethyl acetate (20 mL) then washed by 
H2O (20 mL) and brine (20 mL), respectively. The combined organic layers were dried 
over anhydrous MgSO4 and concentrated in vacuo. The crude residue was purified by 
flash column chromatography (3:1 hexane/acetate) to afford 9 (1.36 g, 56%) as a white 
foam: Rf = 0.2 (3:1 hexane/ ethyl acetate);
 1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.5 
Hz, 2H), 7.78 (d, J = 9 Hz, 2H), 7.04 (d, J = 9 Hz, 2H), 6.99 (d, J = 9 Hz, 2H), 4.97 (brs, 
1H), 4.78 (s, 2H), 4.20 (t, J = 4.5 Hz, 2H), 3.85 (t, J = 4.5 Hz, 2H), 3.63 (t, J = 5 Hz, 2H), 
3.36 (m, 2H), 2.56 (s, 1H), 1.44 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 194.31, 162.05, 
160.67, 155.97, 132.24, 132.10, 131.53, 130.85, 114.37, 114.09, 77.89, 76.11, 70.50, 
69.26, 67.53, 55.88, 28.41, 22.05, 21.99; HRMS (ESI) m/z for C25H29NO6 [M + H]
+
 calcd 
440.2068, found 440.2083. 
 
Biotin-azide (10). Biotin (800 mg, 3.3 mmol), EDCI (1.05 g, 5.5 mmol) and HOBt (836 
mg, 5.5 mmol) were dissolved in anhydrous DMF (18 mL) at 0 °C. 1-amino-11-azido-3, 
6, 9-trioxaundecane (0.54 mL, 2.7 mmol) dissolved in anhydrous DMF (5 mL) was then 
added dropwise. The resulting mixture was stirred at 0 °C for 0.5 h. The ice bath was 
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removed and the resulting mixture was stirred at ambient temperature for 24 h. DCM (20 
mL) was added and the mixture was washed with saturated NaHCO3 solution and brine, 
respectively. The combined DCM layers were dried over anhydrous MgSO4 and removed 
in vacuo. The resulting oil residue was purified by flash column chromatography (9:1 
DCM/CH3OH, spots were visualized by a phosphmolybdate stain) to give desired product 
10 as a white solid (0.98 g, 81%): 
1
H NMR (500 MHz, CDCl3) δ 6.64 (t, J = 5 Hz, 1H), 
6.30 (s, 1H), 5.33 (s, 1H), 4.49 (m, 1H), 4.31-4.33 (m, 1H), 3.62-3.68 (m, 10H), 3.56 (t, J 
= 5 Hz, 2H), 3.44 (t, J = 5.5 Hz, 2H), 3.40 (t, J = 5 Hz, 2H), 3.14–3.16 (m, 1H), 2.92 (dd, 
J = 13, 5 Hz, 1H), 2.74 (d, J = 13 Hz, 1H), 2.21-2.24 (m, 2H), 1.67-1.79 (m, 4H), 1.44-
1.47 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 173.40, 164.20, 70.67, 70.48, 70.10, 70.03, 
69.96, 61.81, 60.27, 55.67, 50.69, 40.53, 39.16, 35.99, 28.26, 28.11, 25.64; HRMS (ESI) 
m/z for C18H32N6O5S [M + H]
+
 calcd 445.2228, found 445.2219. 
 
Boc-probe (11). To a solution of biotin-azide 10 (464 mg, 0.8 mmol) and benzophenone 
alkyne 9 (480 mg, 0.8 mmol) in methanol (20 mL) was added CuSO4·5H2O (40 mg, 0.16 
mmol) and sodium ascorbate (79.2 mg, 0.4 mmol). The reaction mixture was stirred at 
room temperature for 24 h. The resulting light-blue solution was filtered through a pad of 
diatomaceous earth which was washed with MeOH. The filtrate was concentrated in 
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vacuo and the crude residue was dissolved in DCM. The mixture was then washed by 
brine and dried over anhydrous MgSO4. Solvent was removed in vacuo and the resulting 
residue was purified by flash column chromatography (9:1 DCM/CH3OH) to yield the 
desired product 11 (636 mg, 90%) as a white solid: 
1
H NMR (500 MHz, CDCl3) δ 7.87 (s, 
1H), 7.77 (d, J = 9 Hz, 4H), 7.06 (d, J = 9 Hz, 2H), 6.98 (d, J = 9 Hz, 2H), 5.28 (s, 2H), 
4.57 (t, J = 5 Hz, 2H), 4.46-4.49 (dd, J = 7, 6 Hz, 1H), 4.27-4.30 (dd, J = 8, 4.5 Hz, 1H), 
4.19 (t, J = 5 Hz, 2H), 3.89 (t, J = 5 Hz, 2H), 3.85 (t, J = 4.5 Hz, 2H), 3.55-3.66 (m, 10H), 
3.52 (m, 2H), 3.37-3.39 (m, 2H) , 3.34 (m, 2H), 3.10-3.13 (m, 1H), 2.85-2.89 (m, 1H), 
2.71-2.75 (m, 1H), 2.17-2.21 (m, 2H), 1.60-1.69 (m, 4H), 1.38-1.43 (m, 11H); 
13
C NMR 
(125 MHz, CDCl3) δ 194.46, 173.51, 173.48, 164.03, 162.19, 161.58, 156.09, 143.37, 
132.35, 132.33, 131.32, 130.90, 124.42, 114.45, 114.23, 70.78, 70.61, 70.47, 70.24, 70.16, 
69.98, 69.49, 69.36, 67.66, 65.94, 62.17, 61.98, 60.37, 55.65, 50.80, 50.51, 40.59, 39.27, 
36.02, 35.95, 28.53, 28.29, 28.18, 25.67; HRMS (ESI) m/z for C43H61N7O11S [M + H]
+
 
calcd 884.4223, found 884.4229. 
 
Photo-affinity probe (12). Compound 11 (106 mg, 0.12 mmol) was dissolved in DCM 
( 3.0 mL) and TFA (3.0 mL) was added dropwise at room temperature. The mixture was 
stirred for 3 h and then saturated NaHCO3 solution was added dropwise to adjust to 
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afford pH 7. The mixture was extracted with DCM and the combined organic layer was 
washed with brine and dried over anhydrous MgSO4. Solvent was removed in vacuo and 
dried under high vacuum to afford compound 12. MS (ESI) m/z 806.1 [M+Na]
+
. The 
crude material 12 was used to react with 6 in the next step without further purification. 
 
BTT-3 photo-affinity reagent (13). Compound 6a (102 mg, 0.2 mmol), HATU (114 mg, 
0.3 mmol) and TEA (0.06 mL, 0.4 mmol) were mixed in dry DMF (2 mL) and the 
resulting mixture was stirred at room temperature for 10 minutes. Photo-affinity probe 12 
(156.8 mg, 0.2 mmol) was then added and the resulting solution was stirred at ambient 
temperature for 12 h. DCM (5 mL) was added and the mixture was washed with H2O and 
brine, respectively. The combined DCM layer was dried over anhydrous MgSO4 and 
solvent was removed in vacuo. The crude residue was purified by flash chromatography 
( 9:1 DCM/methanol) and dried under high vacuum to afford the desired product 13  as a 
grey solid. MS (ESI) m/z 1274.8 [M+1]
+
. 
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CHAPTER 2. DESIGN AND SYNTHESIS OF SMALL-MOLECULE  
ANTAGONISTS TARGETING UPAR-UPA INTERACTION 
2.1 Introduction 
The urokinase-type plasminogen activator (uPA) is a serine protease that was first 
discovered in 1947 by McFarlane and it was initially isolated from human urine. uPA has 
a cell surface receptor known as the urokinase-type plasminogen activator receptor 
(uPAR). uPAR is a glycosylphosphatidylinositol (GPI) anchored protein containing three 
domains (D1, D2 and D3) (Fig. 2.1).
1,2
 D1 and D3 domains provide the binding site of uPA. 
 
Figure 2.1. Schematic representation of uPAR 
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Only the intact urokinase receptor (uPAR) has a high affinity binding to uPA (1 
nM). When uPA binds to uPAR, it is activated by other proteases. Active uPA will 
subsequently activate plasminogen to trigger the cascade of signaling events that promote 
tumor cell metastasis.
3,4
 It is known that the migration and invasion of tumor cells into 
surrounding tissues are the most common interdependent processes of cancer metastasis.
5
 
There are studies showing that uPAR can be expressed in ECM remodeling,
6-9
 and it 
plays a role in inflammatory and immune responses.
10,11
 This causes cellular stress, injury 
and inflammation.
12
 uPAR is also highly expressed in human cancers,
13-15
 and the 
interaction between GPI anchored-uPAR and uPA is implicated in tumorigenesis,
16
 
invasion,
17-20
 and angiogenesis.
21,22
 
The interaction between uPA and uPAR is believed to lead to activation of cell 
signaling (Fig. 2.2).
2
 On the surface of migrating cells, uPAR binds inactive urokinase 
 
Figure 2.2. The role of uPAR as a protease receptor 
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 (pro-uPA), which is converted to active uPA. Active uPA will activate plasminogen to 
plasmin. The activation of plasmin then triggers a proteolytic cascade that leads to further 
extracellular matrix (ECM) degradation. Active plasmin can activate latent growth 
factors β1 and it can also activate matrix metalloproteinases (MMPs). This process will 
result in the degradation of extracellular matrix that further promotes cancer metastasis. 
 We are interested in developing novel uPA antagonists that can bind into the 
cavity between uPA and its receptor uPAR to modulate the uPA-uPAR interaction and 
block the signaling pathway in cancer cell that are responsible for promoting metastasis 
(Fig. 2.3).  
 
Figure 2.3. Target of uPAR-uPA interaction 
The rational design and synthesis of small molecules targeting uPAR-uPA 
interaction was carried out using docking-based virtual screening.
17,23
 Based on our 
39 
 
previously-published papers, small molecules with 6H-anthra[1,9-cd]isoxazol-6-one core 
structure (IPR-803) and pyrazole core structure (IPR-69) (Fig. 2.4) were discovered and 
synthesized by members of the Meroueh laboratory. These two compounds have shown 
good activity in inhibiting uPAR-uPA protein-protein interaction in cancer cell invasion 
but they did not show very potent in vivo activity. Thus, we are developing antagonists 
with novel structures that bind at higher affinity to uPAR and exhibit greater efficacy.  
 
Figure 2.4. Chemical structures of IPR-69 and IPR-803 
Towards the goal of discovering small molecules with novel core structure and 
better affinity to inhibit uPAR-uPA protein-protein interaction, 500 commercially-
available compounds were purchased and computationally docked in the uPAR. These 
compounds were also tested in the biological assay by members of the Meroueh 
laboratory and three series were found to have modest activity. Their chemical structure 
is shown in Fig. 2.5. The first series is represented by IPR-1110, which has a pyrrolidone 
core structure. The second series contains a pyrrolo[3,4- c]pyrazole scaffold and it is 
represented by IPR-1283, and last series contains a 1,2-disubstituted 1,2-
dihydropyrrolo[3,4-b]indol-3(4H)-one core structure and is represented by IPR-540. 
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Figure 2.5 Chemical structures of IPR-1110, IPR-1283 and IPR-540 
 More IPR-1110 derivatives that emerged from a library were docked to uPAR and 
a binding mode of IPR-1110 with uPAR protein was proposed (Fig. 2.6). Judging from 
the binding mode in Fig. 2.6, there are four hot spot residues on uPA side chain that the 
molecule IPR-1110 mimics. In the structure of IPR-1110, R1 mimics Trp30, R2 mimics 
Phe25 and R3 mimics Tyr24, respectively. Based on this binding mode, the synthetic 
routes to each of the three series compounds that are shown in Fig. 2.5 were proposed and 
derivatives were also designed and synthesized.  
  
 
41 
 
 
Figure 2.6. (a) Binding mode of IPR-1110 shown in capped-sticks. (b)  
          Binding mode of IPR-1110 shown in green ball-and-stick rendering. 
The chemical structure of IPR-1110 is shown in Fig. 2.5 and its binding mode to 
uPAR was proposed (Fig. 2.6). The binding mode of IPR-1110 with uPAR is shown in 
capped-sticks in (Fig. 2.6a). uPAR is shown in grey ribbon and uPAR hot spots are shown 
in capped sticks (orange and red). Here we define hot spots as residues that contribute an 
order of magnitude or more to the binding affinity. Binding mode of IPR-1110, which is 
shown in green ball-and-stick rendering, is shown in (Fig. 2.6b). uPA is shown in purple 
ribbon representation and uPAR is removed for clarity. In addition, the labels correspond 
to the four hot spots on uPA. 
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2.2 Results and Discussion 
2.2.1 Compounds with Pyrrolidone Core Structure 
In this series, IPR-1110 and various derivatives were prepared in a two-step 
procedure. Acetophenone derivatives were first treated with diethyl oxalate then followed 
by the addition of sodium ethoxide to afford the reactive intermediate 1, which exists in 
an enone conformation. Then a three-component Knoevenagel condensation reaction 
with enone 1, benzaldehyde derivatives and free amines was carried out to afford the 
pyrrolidone structures 2 (Scheme 2.1).
24
   
 
Scheme 2.1. Synthetic scheme of IPR-1110 series 
In the first step, enone 1 can be made through a simple Aldol condensation. The 
α-proton of acetophenone is first deprotonated by the strong base sodium ethoxide to 
form a carbanion intermediate. And this carbanion, which is a strong nucleophile will 
subsequently react with diethyl oxalate to afford the desired enone compound. This 
compound was used for next reaction without further purification. It should be noted that 
the enone 1 is very reactive and it will decompose on the TLC plate. Therefore, this 
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compound cannot be purified by flash chromatography. This reaction is straightforward 
and in good yield. However, the only disadvantage of this reaction is that the 
acetophenone sometimes will not completely be converted to the desired product because 
of insufficient sodium ethoxide. Thus, when performing this chemistry, the ratio of 
diethyl oxalate and acetophenone was kept at 1 equivalent and followed by 1.3 equivalent 
of sodium ethoxide. The excess sodium ethoxide will be quenched by adding 2 M HCl 
solution to form ethanol which can be removed under high vacuum conditions. 
In the second step, the mechanism can be divided into two half reactions. The first 
half is a Knoevenagel condensation reaction. Compound 1 is deprotonated to form 
reactive carbanion intermediate that will subsequently react with free benzaldehyde 
derivatives to form an enoate intermediate. In the second half of the reaction, the free 
amine acts as a nucleophile. It will first react with the enoate intermediate through 
Michael addition and then react with the intermolecular carboxylic ester functional group 
to yield the final pyrrolidone compounds. The detailed mechanism of the second step in 
Scheme 2.1 is proposed in Fig. 2.7 using IPR-1110 as example. 
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Figure 2.7. Proposed mechanism of Knoevenagel reaction 
A library containing more than 100,000 compounds that includes the pyrrolidone 
ring system was docked to uPAR protein by computational chemists in the Meroueh 
laboratory. Based on the rankings of Glide scores of various compounds in this library, 
the top 51 compounds were synthesized by other members of Meroueh laboratory 
following Scheme 2.1. They are included here to illustrate to the variation of substituents 
at R1, R2 and R3 that were explored. These compounds were subsequently tested with FP  
and ELISA assays. In addition, SAR study of these 51 compounds was also developed 
(Table 1). 
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Table 1. SAR Study of 51 Synthesized Compounds
a
 
 
Compounds        R1                     R2                  R3              IC50 (µM)   Ki (µM) 
1(IPR-1110) 
  
 
 18 0.7 
2 
  
 
  30 4 
3 
  
 
   91 13 
4 
   
 
      
      
60            5 
5 
 
 
 
 
            56 4 
6 
   
            26 0.8 
7 
   
          29 2 
8 
   
   27              3 
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Table 1. continued 
______________________________________________________________________ 
Compounds        R1                     R2                  R3             IC50 (µM)   Ki (µM) 
9 
  
     
29 2 
10 
  
     
21 1 
11  
       
   
                
20 
                
1 
12  
   
     
            
 
                             
26 
                 
3 
13  
        
    
                     
35 
                 
 2 
14 
  
         
 
   30  2 
15 
  
           
 
   58  2 
16 
 
                            
 
          
 
   N/D  16 
17  
 
                            
 
          
 
   N/D  12 
18 
                          
           
 
    21   3 
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Table 1. continued 
______________________________________________________________________ 
Compounds        R1                     R2                  R3             IC50 (µM)   Ki (µM) 
19 
 
 
           
 
N/D  18 
20 
 
                                   
 
   
 
 N/D N/D 
21 
 
 
            
 
 N/D N/D 
22 
  
           
 
  23 1 
23  
   
           
 
  67  4 
24 
       
       
         77      6 
 
   
  
  25  
   
            
 
        98    8 
  26 
 
  
           
 
        88     19 
  27  
 
                             
 
           
 
        17     1 
  28  
 
                            
 
           
 
        45     2 
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Table 1. continued 
________________________________________________________________________ 
Compounds        R1                     R2                  R3             IC50 (µM) Ki (µM) 
29  
 
                             
 
           
 
  62 2 
30  
 
                            
 
           
 
  N/D N/D 
31 
 
                            
 
           
 
  69 32 
32 
 
                            
 
           
 
  67  8 
33  
 
                            
 
           
 
  93  4 
34  
 
                            
 
           
 
  35  2 
35 
  
 
  37  1 
36 
  
 
  N/D  2 
37 
  
 
  N/D 55 
38 
   
  16 0.9 
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Table 1. continued 
________________________________________________________________________ 
Compounds        R1                     R2                  R3                  IC50(µM)   Ki(µM) 
39 
 
  
  N/D 4 
40 
  
 
  N/D 6 
41 
 
  
N/D 11 
 42 
 
  
N/D 11 
 43 
   
   N/D 17 
 44 
   
   N/D 53 
          45 
 
                             
 
             
 
   N/D 95 
          46 
 
                            
 
           
 
   N/D 2 
          47 
 
                            
 
           
 
   N/D 2 
          48 
 
                            
 
           
 
   47  4 
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Table 1. continued 
________________________________________________________________________ 
Compounds        R1                     R2                  R3             IC50 (µM) Ki (µM) 
       49  
 
                            
 
           
 
    N/D 2 
       50 
 
                            
 
           
 
    23 0.9 
       51 
 
                            
 
           
 
    47 4 
a
N/D: not determined 
From the SAR results in Table 1, IPR-1110 shows the highest inhibition to uPAR-
uPA interaction according to IC50. This suggests that R2 with 3-fluorobenzene and R3 with 
a 4-chloro substituted benzene group are desirable for high affinity interaction with uPAR. 
Introducing a phenethyl moiety into R1 could be an efficient strategy to mimic Trp30 hot 
spot on uPA. An alternative way to modify R1 is to introduce some more rigid aromatic 
groups that can form stronger hydrophobic interaction with Trp30 hot spot into R1. Thus, 
another 8 pyrrolidone derivatives were designed and I synthesized the compounds. These 
compounds were also evaluated for binding and inhibition using a fluorescence 
polarization and ELISA assay as we have described previously.
17 
The biochemical studies 
were conducted by Dr. Degang Liu in the Meroueh laboratory and the results are shown 
in Table 2.  
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Table 2. SAR Study of 8 Synthesized Compounds
 
Compounds R1 
                        
R2                  R3                 IC50 (µM) Ki (µM) 
      2b 
 
                            
 
           
 
24 0.8 
      2c 
 
                            
 
 
16 N/D 
      2e 
 
                            
 
           
 
N/D  8 
      2f 
 
                            
 
  
 22 0.6 
      2g 
 
                            
 
           
 
 N/A N/D 
      2h 
 
                            
 
  
 N/A N/D 
      2i 
 
                            
 
           
 
 N/A N/D 
      2j 
 
                            
 
           
 
  N/A N/D 
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Each of the compounds in Table 2 was tested by Dr. Liu in the Meroueh 
laboratory and used IPR-1110 as control and results were analyzed and summarized in 
Table 3.  
Table 3. Inhibition Activity of 8 Synthesized Compounds
b
 
Compound IC50(µM) Ki(µM) 
2a 18 0.7 
2b 24 0.8 
2c 16 N/D 
2e N/D 8 
2f 22 0.6 
2g N/A N/D 
2h N/A N/D 
2i N/A N/D 
2j N/A N/D 
a
N/D: not determined; 
b
N/A: no activity 
        According to results in Table 3, the IC50 of 2c was 16 µM comparing with our 
best compound IPR-1110, compound 2c showed a slight improvement over IPR-1110. 
These result motivated us to do more research on developing new compounds. It was 
concluded that introducing a biphenyl group with a strong electron withdrawing group 
could be a potential breakthrough. Herein, our future work will mainly focus on 
modification of compound 2c by converting the methyl ester on the biphenyl group into 
different amides.  
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2.2.2 Compounds with Pyrrolo[3, 4- c]pyrazole Scaffold 
The structure of compound IPR-1283 is shown in Fig. 2.5. It was prepared by a two-
step synthesis. In the first step, pyrrolidone 2 was made with the procedure in Scheme 2.1. 
The synthesized compound 2 is added to hydrazine hydride to afford the corresponding 
pyrrolo [3,4-c] pyrazole ring system, namely 3 (Scheme 2.2).
25,26
 
 
Scheme 2.2. Synthetic scheme of IPR-1283 series 
By following the synthetic route in Scheme 2.2, we synthesized compounds 3a 
and 3b and their chemical structures are shown in Fig. 2.8.  But these two compounds did 
not show activity in the ELISA. 
 
Figure 2.8 Chemical structures of 3a and 3b 
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This is likely due to the fact that the pyrrolo[3,4-c]pyrazole scaffold is too rigid too 
enable the R3 group to rotate to fit properly into the cavity on uPAR. The structure 
forces the moiety in R3 to stretch out of the binding pocket on uPAR and move away 
from the position occupied by the Tyr24 hot spot. 
2.2.3  Compounds with 1, 2-Disubstituted 1, 2- dihydropyrrolo 
[3, 4-b]indol-3(4H)-one Core Structure 
IPR-540 is a potential uPA inhibitor that was discovered in the Meroueh 
laboratory by screening commercially-available compounds and its structure is shown in 
Fig 2.5. The synthetic route to IPR-540 derivatives has been proposed (Scheme 2.3).  
The final compound can be prepared by a two-step synthesis. The first step is a 
Mannich reaction. Aldehyde derivatives and free amines will first react to form a Schiff 
base. Then 1H-Indole-2-carboxylic acid is performing as a nucleophile reacted with the 
Schiff base intermediate to afford the final Mannich reaction products.
27
   
  In the second step reaction, the Mannich reaction products afforded in step 1 will 
in turn be dehydrated to generate the final product.
27,28
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Scheme 2.3. Synthetic scheme of IPR-540 series 
Unfortunately, the synthesized compounds did not inhibit the uPAR-uPA 
interaction but they did bind to uPAR. Comparing the chemical structure of IPR-540, the 
only difference is the methyl group on the indole moiety is removed in the synthesized 
compounds. Without the methyl group on the nitrogen atom in the indole moiety, the 
secondary amine could form strong hydrogen bond with Asn22 on uPA and this 
hydrogen bonding interaction will prevent the molecule binding with the hydrophobic 
pocket in R3. Thus, protecting the N atom on indole moiety with a hydrophobic group is 
indispensable. 
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2.3 Experimental 
General Methods: All chemicals were purchased from either Sigma-Aldrich or Acros and 
used as received. Column chromatography was carried out with silica gel GF254 (25-
63μm). Mass Spectra were measured on an Agilent 6520 Mass Q-TOF instrument. 1H 
NMR and 
13
C NMR spectra were recorded on a BRUKER 500 MHz spectrometer, using 
TMS as an internal standard and CDCl3 or DMSO-d6 as solvents. Chemical shifts (δ 
values) and coupling constants (J values) are reported in ppm and hertz, respectively. 
Anhydrous solvent and reagents were all analytically pure and dried through routine 
protocols. All compounds that were evaluated in biological essays had > 95% purity 
using HPLC. 
2.31. Chemical Synthesis of  IPR-1110 Derivatives 
 
Ethyl (Z)-4-(4-chlorophenyl)-2-hydroxy-4-oxobut-2-enoate (1a). To a stirred solution of 
4’-chloroacetophenone (773 mg, 6 mmol) and diethyl oxalate (0.81 mL, 6 mmol) in 
anhydrous THF (12 mL) was added sodium ethoxide (3 M in ethanol) (2.7 mL, 7.8 mmol) 
at 0 °C over 15min. The mixture was warmed to ambient temperature and stirred for 20 h. 
The resulting dark red solution was cooled to 0 °C in an ice bath, quenched with 2 M HCl 
solution and extracted with ethyl acetate (3 x 15 mL). The combined organic layer was 
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dried over anhydrous MgSO4 and removed in vacuo. Crude residue was kept in 
refrigerator for 24 h and triturated with hexane. The resulting product was dried under 
high vacuum to give a light yellow power (1.34 g, 88%): 
1
H NMR (500 MHz, CDCl3) δ 
7.92 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.02 (s, 1H), 4.37-4.41 (q, J = 7 Hz, 
2H), 1.40 (t, J = 7 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 189.34, 169.94, 162.00, 
140.26, 133.24, 129.22, 129.18, 97.72, 62.68, 14.04; HRMS (ESI) m/z for C12H11ClO4 
[M + H]
+
 calcd 255.0419, found 255.0421. 
 
Ethyl (Z)-4-(3-chlorophenyl)-2-hydroxy-4-oxobut-2-enoate (1b). Compound 1b was 
prepared from 3’-chloroacetophenone in a manner similar to that described for compound 
1a. Yield 92%, light yellow solid: 
1
H NMR (500 MHz, CDCl3) δ 15.09 (brs, 1H), 7.96 (t, 
J = 2 Hz, 1H), 7.85-7.87 (m, 1H), 7.56-7.58 (m, 1H), 7.44 (t, J = 8 Hz, 1H), 7.02 (s, 1H), 
4.38-4.43 (q, J = 7 Hz, 2H), 1.41 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 
189.12, 170.32, 161.96, 136.58, 136.26, 133.60, 130.20, 127.90, 125.93, 97.95, 62.78, 
14.08; HRMS (ESI) m/z for C12H11ClO4 [M + H]
+
 calcd 255.0419, found 255.0423. 
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1-(3-Bromo-4-methylphenyl)-4-(4-chlorobenzoyl)-5-(3-fluorophenyl)-3-hydroxy-1,5-
dihydro-2H-pyrrol-2-one (2a). Compound 1a (50.9 mg, 0.2 mmol) was dissolved in 
acetonitrile (2 mL) and 3-bromo-4-methylaniline (37.2 mg, 0.2 mmol) was added 
subsequently. Yellow precipitate was formed in the solution and the mixture was stirred 
under room temperature for 30 min. 3-Fluorobenzaldehyde (21.2 μL, 0.2 mmol) was 
added and the resulting mixture was stirred at ambient temperature for 20 h. Solvent was 
removed in vacuo to yield yellow solid and the residue was triturated with ice-cold 
diethyl ether. The resulting product was filtered, washed with ice-cold diethyl ether and 
dried under high vacuum to give a snow-white solid (27.9 mg, 28%): 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.94 (d, J = 2 Hz, 1H), 7.74 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 2H), 
7.48-7.50 (dd, J = 8, 2 Hz, 1H), 7.30 (t, J = 8.5 Hz, 2H), 7.24-7.26 (m, 2H), 6.94-6.98 (m, 
1H), 6.33 (s, 1H), 2.25 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 187.77, 164.53, 162.89, 
160.95, 137.45, 136.63, 136.20, 134.37, 130.92, 130.62, 130.30, 130.23, 128.31, 125.71, 
123.89, 123.70, 121.56, 115.02, 114.85, 114.66, 99.50, 60.45, 21.75; HRMS (ESI) m/z 
for C24H16BrClFNO3 [M + H]
+
 calcd 500.0059, found 500.0058. 
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1-([1,1'-Biphenyl]-4-yl)-4-(4-chlorobenzoyl)-5-(3-fluorophenyl)-3-hydroxy-1,5-dihydro-
2H-pyrrol-2-one (2b). Compound 2b was prepared by a three-component Knoevenagel 
condensation of 1a, 4-aminobiphenyl and 3-fluorobenzaldehyde in a manner similar to 
that described for 2a. And 20% DMAP was added. Yield 37%, white solid: 
1
H NMR 
(500 MHz, DMSO-d6) δ 7.73-7.76 (m, 4H), 7.62-7.65 (m, 4H), 7.53 (d, J = 8.5 Hz, 2H), 
7.43 (t, J = 7.5 Hz, 2H), 7.32-7.36 (m, 2H), 7.27-7.30 (m, 1H), 7.23-7.26 (m, 1H), 6.96 (t, 
J = 8 Hz, 1H), 6.40 (s, 1H); 
13
C NMR (125 MHz, DMSO-d6) δ 187.88, 164.49, 162.90, 
160.96, 151.05, 139.58, 137.50, 137.03, 136.63, 135.54, 130.62, 128.86, 128.32, 127.39, 
126.88, 126.44, 123.85, 122.77, 119.14, 114.98, 114.82, 114.66, 60.47; HRMS (ESI) m/z 
for C29H19ClFNO3 [M + H]
+
 calcd 484.1110, found 484.1067. 
 
Methyl-4'-(3-(4-chlorobenzoyl)-2-(3-fluorophenyl)-4-hydroxy-5-oxo-2,5-dihydro-1H-
pyrrol-1-yl)-[1,1'-biphenyl]-3-carboxylate (2c). Compound 2c was prepared by a three-
component Knoevenagel condensation of 1a, methyl 4'-amino-(1,1'-biphenyl)-3-
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carboxylate and 3-fluorobenzaldehyde in a manner similar to that described for 2a. And 
20% DMAP was added. Yield 34%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 8.14 
(s, 1H), 7.92 (m, 2H), 7.69-7.77 (m, 6H), 7.54-7.59 (m, 3H), 7.30-7.36 (m, 3H), 6.96 (s, 
1H), 6.41 (s, 1H), 3.88 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 187.83, 166.08, 164.57, 
162.89, 160.95, 139.69, 127.47, 136.64, 136.03, 135.83, 131.27, 130.63, 130.32, 129.45, 
128.31, 128.01, 127.09, 126.92, 123.86, 122.83, 119.08, 114.83, 114.66, 78.94, 60.42, 
52.20; HRMS (ESI) m/z for C31H21ClFNO5 [M + H]
+
 calcd 542.1165, found 542.1149. 
 
Methyl-4'-(3-(3-chlorobenzoyl)-2-(3-fluorophenyl)-4-hydroxy-5-oxo-2,5-dihydro-1H-
pyrrol-1-yl)-[1,1'-biphenyl]-3-carboxylate (2d). Compound 2d was prepared by a three-
component Knoevenagel condensation of 1a, methyl 4'-amino-(1,1'-biphenyl)-3-
carboxylate and 3-fluorobenzaldehyde in a manner similar to that described for 2a. And 
20% DMAP was added. Yield 36%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 8.14 
(s, 1H), 7.92 (d, J = 7 Hz, 2H), 7.77 (d, J = 8 Hz, 2H), 7.74 (s, 1H), 7.68 (d, J = 7.5 Hz, 
3H), 7.64 (d, J = 7.5 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.38 (d, J 
= 9.5 Hz, 1H), 7.32 (d, J = 7 Hz, 1H), 7.26 (d, J = 6 Hz, 1H), 6.96 (m, 1H), 6.39 (s, 1H), 
3.87 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 187.86, 166.09, 160.95, 139.70, 136.05, 
135.85, 132.97, 132.20, 131.30, 130.33, 130.19,  129.48, 128.29, 128.02, 127.31, 127.10, 
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126.93, 123.95, 122.89, 114.94, 114.78, 60.42, 52.22; HRMS (ESI) m/z for 
C31H21ClFNO5 [M + H]
+
 calcd 542.1165, found 542.1166.  
 
4-(4-Chlorobenzoyl)-1-(3,4-dimethoxyphenethyl)-5-(3-fluorophenyl)-3-hydroxy-1,5-
dihydro-2H-pyrrol-2-one (2e). Compound 2e was prepared by a three-component 
Knoevenagel condensation of 1a, 3,4-dimethoxyphenethylamine and 3-
fluorobenzaldehyde in a manner similar to that described for 2a. Yield 66%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 7.69 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8 Hz, 2H), 7.34-
7.38 (m, 1H), 7.13-7.16 (m, 3H), 6.83 (d, J = 8 Hz, 1H), 6.71 (d, J = 1.5 Hz, 1H), 6.63-
6.65 (dd, J = 8.5, 1.5 Hz, 1H), 3.81-3.87 (m, 1H), 3.70 (s, 3H), 3.69 (s, 3H), 2.81-2.84 (m, 
1H), 2.73-2.76 (m, 1H), 2.62-2.65 (m, 1H); 
13
C NMR (125 MHz, DMSO-d6) δ 188.12, 
163. 94, 166.13, 161.66, 149.14, 147.89, 137.55, 137.41, 131.45, 131.04, 128.64, 124.28, 
120.97, 112.83, 112.38, 60.68, 55.97, 55.83, 42.20, 33.49; HRMS (ESI) m/z for 
C27H23ClFNO5 [M + H]
 +
 calcd 496.1322, found 496.1321. 
 
62 
 
 
4-(3-Chlorobenzoyl)-1-(3,4-dichlorophenethyl)-5-(3-fluorophenyl)-3-hydroxy-1,5-
dihydro-2H-pyrrol-2-one (2f). Compound 2f was prepared by a three-component 
Knoevenagel condensation of 1b, 3-fluorobenzaldehyde and 3, 4-dichlorophenethylamine 
in a manner similar to that described for 2a. Yield 68%, white solid: 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.98 (s, 1H), 7.70 (s, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.54-7.56 (m, 1H), 7.50 
(d, J = 8.5 Hz, 1H), 7.42-7.44 (m, 2H), 7.35-7.36 (m, 1H), 7.14-7.20 ( m, 2H), 7.09 (t, J = 
7.5 Hz, 1H), 5.42 (s, 1H), 3.82-3.86 (m, 1H), 2.86-2.88 (m, 1H), 2.79 (m, 2H); 
13
C NMR 
(125 MHz, DMSO-d6) δ 186.10, 165.96, 163.08, 161.14, 150.73, 140.04, 138.53, 132.61, 
131.31, 131.04, 130.81, 130,65, 130.33, 129.77, 129.40, 129.28, 129.09, 128.90, 128.23, 
127.19, 123.74, 114.75, 59.95, 41.09, 32.28; HRMS (ESI) m/z for C25H17Cl3FNO3 [M + 
H]
 +
 calcd 504.0331, found 504.0334.  
 
4-(4-Chlorobenzoyl)-5-(3-fluorophenyl)-3-hydroxy-1-(4-methylbenzyl)-1,5-dihydro-2H-
pyrrol-2-one (2g). Compound 2g was prepared by a three-component Knoevenagel 
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condensation of 1a, 4-methylbenzylamine and 3-fluorobenzaldehyde in a manner similar 
to that described for 2a. Yield 59%, light yellow solid: 
1
H NMR (500 MHz, DMSO-d6) δ 
7.71 (d, J = 7.5 Hz, 2H), 7.49 (d, J = 8 Hz, 2H), 7.34-7.35 (m, 1H), 7.09-7.11 (m, 5H), 
6.98 (d, J = 7 Hz, 2H), 5.20 (s, 1H), 4.83 (d, J = 15 Hz, 1H), 3.73 (d, J = 15 Hz, 1H), 2.27 
(s, 3H); HRMS (ESI) m/z for C25H19ClFNO3 [M + H]
+
 calcd 436.1110, found 436.1111. 
 
1-([1,1'-Biphenyl]-4-ylmethyl)-4-(4-chlorobenzoyl)-5-(3-fluorophenyl)-3-hydroxy-1,5-
dihydro-2H-pyrrol-2-one (2h). Compound 2h was prepared by a three-component 
Knoevenagel condensation of 1a, 4-phenylbenzylamine and 3-fluorobenzaldehyde in a 
manner similar to that described for 2a. Yield 62%, white solid: 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.72 (d, J = 8.5 Hz, 2H), 7.63 (d, J = 7.5 Hz, 2H), 7.59 (d, J = 8 Hz, 2H), 
7.49 (d, J = 8.5 Hz, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.32-7.37 (m, 2H), 7.18 (d, J = 8 Hz, 
2H), 7.14 (d, J = 8 Hz, 2H), 7.09 (t, J = 8.5 Hz, 1H), 5.31 (s, 1H), 4.86 (d, J = 15.5 Hz, 
1H), 3.90 (d, J = 15 Hz, 1H); HRMS (ESI) m/z for C30H21ClFNO3 [M + H]
+
 calcd 
498.1267, found 498.1272. 
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4-(4-Chlorobenzoyl)-1-(4-fluorophenethyl)-5-(3-fluorophenyl)-3-hydroxy-1,5-dihydro-
2H-pyrrol-2-one (2i). Compound 2i was prepared by a three-component Knoevenagel 
condensation of 1a, 4-fluorophenethylamine and 3-fluorobenzaldehyde in a manner 
similar to that described for 2a. Yield 73%, yellow-white solid: 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.70 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 7.35-7.39 (m, 1H), 7.16-
7.20 (m, 4H), 7.07-7.13 (m, 3H), 5.41 (s, 1H), 3.80-3.86 (m, 1H), 2.79-2.87 (m, 2H), 
2.71-2.75 (m, 1H); HRMS (ESI) m/z for C25H18ClF2NO3 [M + H]
+
 calcd 454.1016, found 
454.1008. 
 
4-(4-Chlorobenzoyl)-5-(3-fluorophenyl)-3-hydroxy-1-(2-phenoxyethyl)-1,5-dihydro-2H-
pyrrol-2-one (2j). Compound 2j was prepared by a three-component Knoevenagel 
condensation of 1a, 2-phenoxyethylamine, and 3-fluorobenzaldehyde in a manner similar 
to that described for 2a. Yield 72%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 7.97 
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(s, 1H), 7.72 (d, J = 8 Hz, 2H), 7.47 (d, J = 8 Hz, 2H), 7.35 (m, 1H), 7.27-7.28 (m, 2H), 
7.19 (d, J = 7.5 Hz, 1H), 7.09 (m, 1H), 6.97-6.99 (m, 1H), 6.93-6.94 (m, 1H), 6.90 (d, J = 
7 Hz, 1H), 5.56 (s, 1H), 3.93-4.15 (m, 2H), 3.02 (m, 2H); HRMS (ESI) m/z for 
C25H19ClFNO4  [M + H]
+
 calcd 452.1059, found 452.1036.
4-(4-Chlorobenzoyl)-5-(3-fluorophenyl)-3-hydroxy-1-(3-morpholinopropyl)-1,5-dihydro-
2H-pyrrol-2-one (2k). Compound 2k was prepared by a three-component Knoevenagel 
condensation of 1a, 3-morpholinopropylamine and 3-fluorobenzaldehyde in a manner 
similar to that described for 2a. Yield 67%, white solid: 
1
H NMR (500 MHz, DMSO-d6)
δ 7.82 (s, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 8 Hz, 1H), 7.33 (t, J = 8 Hz, 2H), 
7.14 (t, J = 9 Hz, 2H), 7.04-7.07 (m, 1H), 5.32 (s, 1H), 3.72 (m, 4H), 2.89 (m, 4H), 2.75 
(m, 2H), 2.63-2.69 (m, 2H), 1.77 (m, 1H), 1.71 (m, 1H); HRMS (ESI) m/z for 
C24H24ClFN2O4 [M + H]
+
 calcd 459.1481, found 459.1489.
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2.32. Chemical Synthesis of  IPR-1283 Derivatives 
 
5-(3-Bromo-4-methylphenyl)-3-(4-chlorophenyl)-4-(3-fluorophenyl)-4,5-
dihydropyrrolo[3,4-c]pyrazol-6(1H)-one (3a). Compound 2a (49.8 mg, 0.1 mmol) was 
dissolved in acetic acid (2 mL) and the mixture was cooled to 0 °C in an ice bath. To the 
solution was added 50-60% hydrazine hydride (0.3 mL, 1.0 mmol) over 5 min. The 
resulting solution was stirred at 0 °C for 15 min then was heated to reflux for 6 h. The 
reaction was monitored by LC/MS. After the reaction was completed, the mixture was 
cooled to room temperature and ice-cold H2O (2 mL) was added to yield white precipitate. 
The resulting solid was filtered off, washed with ice-cold H2O and dried under high 
vacuum to afford the desired product 3a as a white solid (30.7 mg, 62%): 
1
H NMR (500 
MHz, DMSO-d6) δ 7.94 (d, J = 2 Hz, 1H), 7.74 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 
2H), 7.48-7.50 (dd, J = 8, 2 Hz, 1H), 7.29-7.32 (m, 2H), 7.24-7.26 (m, 2H), 6.94-6.98 (m, 
1H), 6.33 (s, 1H), 2.25 (s, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 187.77, 164.53, 162.89, 
160.95, 137.45, 136.63, 135.20, 134.37, 130.92, 130.62, 130.30, 130.23, 128.31, 125.71, 
123.89, 123.70, 121.56, 115.02, 114.85, 114.66, 99.50, 60.45, 21.75; HRMS (ESI) m/z 
for C24H16BrClFN3O [M + H]
+
 calcd 496.0222, found 496.0208. 
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5-([1,1'-Biphenyl]-4-yl)-3-(4-chlorophenyl)-4-(3-fluorophenyl)-4,5-dihydropyrrolo[3,4-
c]pyrazol-6(1H)-one (3b). Compound 3b was prepared from 2b in a manner similar to 
that described for 3a. Yield 59%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 14.24 
(brs, 1H), 7.68 (d, J = 9 Hz, 2H), 7.64 (m, 4H), 7.59 (d, J = 8 Hz, 2H), 7.47 (m, 2H), 7.42 
(t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 1H), 7.22-7.27 (m, 3H), 6.98 (t, J = 8.5 Hz, 1H), 
6.92 (s, 1H); 
13
C NMR (125 MHz, DMSO-d6) δ 162.98, 161.04, 139.59, 139.20, 136.77, 
136.63, 133.18, 130.77, 130.71, 128.84, 127.67, 127.31, 126.79, 126.41, 123.45, 115.40, 
115.23, 114.67, 114.49, 58.90, 30.62; HRMS (ESI) m/z for C29H19ClFN3O [M + H]
+
 
calcd 480.1273, found 480.1275. 
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2.33. Chemical Synthesis of  IPR-540 Derivatives 
 
3-((Phenethylamino)(phenyl)methyl)-1H-indole-2-carboxylic acid (4a). Indole-2-
carboxylic acid (483.5 mg, 3.0 mmol), benzaldehyde (0.37 mL, 3.6 mmol) and 
phenylethylamine (0.57 mL, 4.5 mmol) were mixed in 95% ethanol (6 mL) and the 
resulting solution was heated to reflux for 8 h. The reaction was cooled to room 
temperature and placed into freezer for 48 h. The resulting white precipitate was filtered 
and washed with minimum amount of ice-cold ethanol. The solid was dried under high 
vacuum to yield the desired product 4a (233 mg, 21%): 
1
H NMR (500 MHz, DMSO-d6) δ 
11.40 (s, 1H), 7.69 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 8 Hz, 1H), 7.36 (t, J = 7.5 Hz, 3H), 
7.28-7.31 (m, 2H), 7.26 (d, J = 7.5 Hz, 2H), 7.20-7.22 (m, 1H), 7.17 (d, J = 7 Hz, 2H), 
7.11-7.14 (m, 1H), 6.96-6.99 (m, 1H), 5.74 (s, 1H), 3.01-3.08 (m, 1H), 2.96-3.00 (m, 2H), 
2.91-2.95 (m, 1H); 
13
C NMR (125 MHz, DMSO-d6) δ 164.59, 138.88, 137.70, 134.49, 
131.17, 128.74, 128.57, 128.43, 128.32, 127.91, 126.57, 126.52, 123.17, 119.31, 118.97, 
112.31, 112.07, 57.36, 46.93, 32.35; HRMS (ESI) m/z for C24H22N2O2 [M + H]
+
 calcd 
371.1754, found 371.1752. 
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3-(((2,4-Dichlorophenethyl)amino)(3-fluorophenyl)methyl)-1H-indole-2-carboxylic acid 
(4b). Compound 4b was prepared in a manner similar to that described for 4a. Yield 
33.8%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 11.47 (s, 1H), 7.68 (d, J = 8.5 Hz, 
1H), 7.55 (s, 1H), 7.51 (d, J = 8.5 Hz, 2H), 7.42 (t, J = 8 Hz, 1H), 7.37 (d, J = 8.5 Hz, 
1H), 7.35 (d, J = 1 Hz, 2H), 7.14 (t, J = 8 Hz, 2H), 7.00 (t, J = 7.5 Hz, 1H), 5.81 (s, 1H), 
2.97-3.10 (m, 4H); 
13
C NMR (125 MHz, DMSO-d6) δ 164.30, 163.03, 161.08, 141.74, 
134.58, 134.35, 133.97, 132.25,  130.80, 128.79, 127.58, 126.46, 123.94, 123.38, 119.47, 
119.07, 115.20, 115.04, 114.68, 114.50, 112.37, 56.64, 44.86, 29.92; HRMS (ESI) m/z 
for C24H19Cl2FN2O2 [M + H]
+
 calcd 457.0880, found 457.0883. 
 
2-Phenethyl-1-phenyl-1,4-dihydropyrrolo[3,4-b]indol-3(2H)-one (5a). Compound 4a 
(111 mg, 0.3 mmol), HATU (171 mg, 0.45 mmol) and TEA (0.08 mL, 0.6 mmol) were 
dissolved in anhydrous DMF (5 mL) and the resulting mixture was stirred at room 
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temperature for 20 h. H2O was added and the mixture was extracted with ethyl acetate. 
The combined organic layer was washed with saturated NaHCO3 solution and brine, 
respectively. The organic extracts were dried over anhydrous MgSO4 and concentrated in 
vacuo. The crude residue was purified by flash chromatography (hexane/ethyl acetate = 
3:1) to afford desired compound 5a as a white solid (26.4 mg, 25%): 
1
H NMR (500 MHz, 
DMSO-d6) δ 11.96 (s, 1H), 7.45 (d, J = 8 Hz, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.33-7.34 (m, 
1H), 7.26 (t, J = 7 Hz, 2H), 7.23-7.24 (m, 1H), 7.22 (m, 1H), 7.19 (d, J = 8 Hz, 3H), 7.15-
7.16 (m, 2H), 6.97- 7.00 (m, 1H), 5.62 (s, 1H), 3.92-3.98 (m, 1H), 2.96-3.02 (m, 1H), 
2.88-2.92 (m, 1H), 2.69-2.75 (m, 1H); 
13
C NMR matched that previously reported;
27
  
HRMS (ESI) m/z for C24H20N2O [M + H]
+
 calcd 353.1648, found 353.1660. 
 
2-(2,4-Dichlorophenethyl)-1-(3-fluorophenyl)-1,4-dihydropyrrolo[3,4-b]indol-3(2H)-one 
(5b). Compound 5b was prepared from 4b in a manner similar to that described for 5a. 
Yield 19.6%, white solid: 
1
H NMR (500 MHz, DMSO-d6) δ 11.99 (s, 1H), 7.52 (s, 1H), 
7.44 (d, J = 9.5 Hz, 1H), 7.38-7.41 (m, 1H), 7.31 (d, J = 1.5 Hz, 2H), 7.22-7.25 (m, 2H), 
7.13-7.17 (m, 1H), 7.07-7.09 (m, 2H), 7.00 (t, J = 7 Hz, 1H), 5.79 (s, 1H), 3.91-3.97 (m, 
1H), 3.06-3.11 (m, 1H), 2.98-3.03 (m, 1H), 2.86-2.93 (m, 1H); 
13
C NMR (125 MHz, 
DMSO-d6) δ 163.31, 162.10, 161.37, 141.32, 140.35, 135.54, 134.00, 133.22, 132.33, 
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131.87, 131.02, 129.36, 128.65, 127.38, 124.00, 123.24, 120.76, 120.16, 119.10, 115.17, 
114.13, 113.52, 59.39, 31.64; HRMS (ESI) m/z for C24H17Cl2FN2O [M + H]
+
 calcd 
439.0775, found 439.0773. 
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Figure A1. The 500 MHz 
1
H NMR spectrum of 1 in CDCl3 
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C NMR spectrum of 1 in CDCl3 
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Figure A3. The 500 MHz 
1
H NMR spectrum of 2 in CDCl3 
 
80 
 
 
 
 
 
 
 
 
 
 
200 180 160 140 120 100 80 60 40 20 0 ppm
2
1
.
4
4
1
1
9
.
8
1
1
2
2
.
5
5
1
2
7
.
9
6
1
2
8
.
5
5
1
2
8
.
9
2
1
2
9
.
5
4
1
2
9
.
7
3
1
3
0
.
9
3
1
3
9
.
1
4
1
3
9
.
4
1
1
5
4
.
9
5
1
8
5
.
3
7
Figure A4. The 125 MHz 
13
C NMR spectrum of 2 in CDCl3 
 
81 
 
 
 
 
 
 
 
 
 
10 9 8 7 6 5 4 3 2 1 0 ppm
2
.
4
2
6
3
.
8
7
3
6
.
9
4
4
6
.
9
6
2
7
.
2
8
9
7
.
3
0
4
7
.
3
2
0
7
.
3
3
5
7
.
3
5
0
7
.
3
5
3
7
.
3
8
4
7
.
4
6
8
7
.
4
8
3
7
.
4
8
4
7
.
5
0
0
7
.
5
9
9
7
.
6
1
5
7
.
7
8
5
7
.
7
8
7
7
.
8
0
2
7
.
8
6
1
7
.
8
9
2
7
.
9
6
6
7
.
9
8
4
8
.
3
2
8
3
.0
0
2
.9
8
1
.9
9
1
.9
4
0
.7
9
1
.3
5
2
.0
2
1
.9
2
1
.9
5
0
.9
8
1
.9
7
0
.9
6
Figure A5. The 500 MHz 
1
H NMR spectrum of 3 in CDCl3 
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H NMR spectrum of 4  in CDCl3 
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Figure A11. The 500 MHz 
1
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Figure B3. The 500 MHz 
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H NMR spectrum of 1b  in CDCl3 
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Figure B5. The 500 MHz 
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H NMR spectrum of 2a in DMSO-d6 
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Figure B8. The 125 MHz 
13
C NMR spectrum of 2b in DMSO-d6 
115 
 
 
  
-111 10 9 8 7 6 5 4 3 2 1 0 ppm
2
.
5
0
3
3
.
3
3
6
3
.
8
7
6
6
.
4
0
8
6
.
9
6
4
7
.
2
9
5
7
.
3
5
9
7
.
5
4
1
7
.
5
8
7
7
.
6
9
0
7
.
7
6
9
7
.
9
2
4
8
.
1
4
1
3
.0
0
0
.8
3
0
.9
8
2
.9
9
2
.8
7
6
.0
0
2
.2
7
1
.4
2
Figure B9. The 500 MHz 
1
H NMR spectrum of 2c in DMSO-d6 
116 
 
 
  
200 180 160 140 120 100 80 60 40 20 0 ppm
5
2
.
2
0
6
0
.
4
2
7
8
.
6
7
7
8
.
9
4
7
9
.
2
0
1
1
4
.
6
6
1
1
4
.
8
3
1
1
9
.
0
8
1
2
2
.
8
3
1
2
3
.
8
6
1
2
6
.
9
2
1
2
7
.
0
9
1
2
8
.
0
1
1
2
8
.
3
1
1
2
9
.
4
5
1
3
0
.
3
2
1
3
0
.
6
3
1
3
1
.
2
7
1
3
5
.
8
3
1
3
6
.
0
3
1
3
6
.
6
4
1
3
7
.
4
7
1
3
9
.
6
9
1
6
0
.
9
5
1
6
2
.
8
9
1
6
4
.
5
7
1
6
6
.
0
8
1
8
7
.
8
3
Figure B10. The 125 MHz 
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Figure B11. The 500 MHz 
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Figure B13. The 500 MHz 
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H NMR spectrum of 2e in DMSO-d6 
120 
 
 
  
200 180 160 140 120 100 80 60 40 20 0 ppm
3
3
.
4
9
4
2
.
2
0
5
5
.
8
3
5
5
.
9
7
6
0
.
6
8
1
1
2
.
3
8
1
1
2
.
8
3
1
2
0
.
9
7
1
2
4
.
2
8
1
2
8
.
6
4
1
3
1
.
0
4
1
3
1
.
4
5
1
3
7
.
4
1
1
3
7
.
5
5
1
4
7
.
8
9
1
4
9
.
1
5
1
6
1
.
6
6
Figure B14. The 125 MHz 
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Figure B15. The 500 MHz 
1
H NMR spectrum of 2f in DMSO-d6 
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Figure B18. The 500 MHz 
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H NMR spectrum of 2h in DMSO-d6 
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Figure B19. The 500 MHz 
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H NMR spectrum of 2i in DMSO-d6 
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Figure B20. The 500 MHz 
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Figure B21. The 500 MHz 1H NMR spectrum of 2k in DMSO-d6 
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